… with Amyotrophic Lateral Sclerosis, the … Amyotrophic Lateral Sclerosis experienced that
treatment with MI-E was exhausting and inefficient. Despite adjustments of settings, all treatment …

… treatment of spasticity in ALS patients, as they can control spasticity with safety and efficacy
in multiple sclerosis [58… cohort study has revealed high treatment satisfaction with nabiximols, …

… its safety and efficacy and its use as a complementary therapy along with other approved
drugs. … Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded …

… Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that affects adults and
… from bench to bedside in the field of ALS treatment. More than 160 drug candidates or ther…

Amyotrophic lateral sclerosis (ALS) is a motor neuron disease characterized by progressive
loss of upper and lower motor neurons. Despite significant scientific efforts in the last …

… This opposes the high attrition of drugs during bench-to-bedside translation … drug development.
These findings emphasize a careful application of these model systems for ALS therapy …

… the small study sample and the low treatment doses received by patients. Another silencing
… RNAi therapy from the bench to the bedside is the lack of an in vivo biomarker of therapeutic …

… could be a barrier to axonal outgrowth/regeneration during patient treatment. Despite the
gap from bench to bedside, STMN2 is a potential therapeutic target for TDP-43 proteinopathy. …

… ), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and Huntington’s disease
(… and treatments that can reshape the gut microbiome, serving as potential therapies for NDs (…

… treatment has been found for amyotrophic lateral sclerosis (… the disease, multiple medical
therapies have been proposed … translational researches from bench to bedside in various …